RT info:eu-repo/semantics/article
T1 Situación actual de los nuevos anticoagulantes orales
A1 García Frade, Luis Javier
A1 González Mena, Beatriz
A1 Albarrán Severo, Beatriz
A1 Andujar Troncoso, Giselle
A1 Cidoncha Morcillo, Borja
A2 Ediciones Universidad de Valladolid
AB For more than half a century, vitamin K antagonists have defined oral anticoagulant therapy for the long-term management of thrombotic disorders. Despite its clinical efficacy, vitamin-antagonists have multiple, well-known limitations, including numerous interactions with other drugs and the need for regular blood monitoring and dose adjustments. The alterna- tive new oral anticoagulants that are at least equally efficacious, safer and easier to administer, open a new era in antithrombotic treatment. These agents are directed against either thrombin (Dabigatran) or factor Xa (Rivaroxabán and Apixabán), have a half-life around 12 hours in patients with normal renal function and a time to peak anticoagulant activity of two or three hours. Though thousands of patients have been treated in clinical trials in venous and arterial thrombosis, more experience is needed in ordinary practice. Open questions remain such as how to manage hemorrhage, invasive procedures particularly on emergency, resumption following procedures, need of bridging with heparin, treatment of overdoses and the present absence of antidote.
SN 0210-6523
YR 2013
FD 2013
LK http://uvadoc.uva.es/handle/10324/23849
UL http://uvadoc.uva.es/handle/10324/23849
LA spa
NO Anales de la Real Academia de Medicina y Cirugía de Valladolid, 2013, N.50, pags.99-112
DS UVaDOC
RD 24-nov-2024